Contract facts
NONENo full NAICS 325413 intel page yet. Browse NAICS intelligence
PURSUANT TO FEDERAL ACQUISITION REGULATION (FAR) 52.217-9, OPTION TO EXTEND THE TERM OF THE CONTRACT, W81K00-22-P-0269 WITH DIASORIN MOLECULAR, LLC. IS HEREBY EXTENDED FOR THE PERIOD 01 OCTOBER 2025 - 30 SEPTEMBER 2026 (OPTION PERIOD 3). is a federal NONE award for W40m Mrc0 West held by Diasorin Molecular LLC. Estimated value $140K ($26K obligated). Current period of performance ends Sep 30, 2027. Last award drew 1 bidder. Place of performance: JBSA FT SAM HOUSTON TX. Related solicitation W81K0022Q0165.
PURSUANT TO FEDERAL ACQUISITION REGULATION (FAR) 52.217-9, OPTION TO EXTEND THE TERM OF THE CONTRACT, W81K00-22-P-0269 WITH DIASORIN MOLECULAR, LLC. IS HEREBY EXTENDED FOR THE PERIOD 01 OCTOBER 2025 - 30 SEPTEMBER 2026 (OPTION PERIOD 3).
Recompete timing
PublicCurrent PoP ends Sep 30, 2027 (405 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Incumbent footprint
Public recordDiasorin Molecular LLC — $16.5M obligated across 436 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W81K0022P0269?
W81K0022P0269 (FAR pursuant federal acquisition regulation) is a W40m Mrc0 West award with a potential value of $140K, currently held by Diasorin Molecular LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is W81K00-22-P-0269?
W81K00-22-P-0269 is the dashed form of PIID W81K0022P0269 (FAR pursuant federal acquisition regulation), held by Diasorin Molecular LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded W81K0022P0269?
W40m Mrc0 West awarded W81K0022P0269 to Diasorin Molecular LLC (potential $140K).
Who is the incumbent on W81K0022P0269?
Diasorin Molecular LLC is the incumbent with $16.5M across 436 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2027.
When does Diasorin Molecular LLC’s W81K0022P0269 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.